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Abstract
Background: Point-of-care (POC) CD4 testing increases patient accessibility to assessment of antiretroviral therapy
eligibility. This review evaluates field performance in low and middle-income countries (LMICs) of currently available
POC CD4 technologies.
Methods: Eight electronic databases were searched for field studies published between January 2005 and January
2015 of six POC CD4 platforms: PointCare NOW™, Alere Pima™ CD4, Daktari™ CD4 Counter, CyFlow® CD4 miniPOC,
BD FACSPresto™, and MyT4™ CD4. Due to limited data availability, meta-analysis was conducted only for diagnostic
performance of Pima at a threshold of 350 cells/μl, applying a bivariate multi-level random-effects modelling
approach. A covariate extended model was also explored to test for difference in diagnostic performance between
capillary and venous blood.
Results: Twenty seven studies were included. Published field study results were found for three of the six POC
CD4 tests, 24 of which used Pima. For Pima, test failure rates varied from 2 to 23 % across study settings. Pooled
sensitivity and specificity were 0.92 (95 % CI = 0.88–0.95) and 0.87 (95 % CI = 0.85–0.88) respectively. Diagnostic
performance by blood sample type (venous vs. capillary) revealed non-significant differences in sensitivity (0.94 vs 0.
89) and specificity (0.86 vs 0.87), respectively in the extended model (Wald χ2(2) = 4.77, p = 0.09).
Conclusions: POC CD4 testing can provides reliable results for making treatment decision under field conditions in
low-resource settings. The Pima test shows a good diagnostic performance at CD4 cut-off of 350 cells/μl. More data
are required to evaluate performance of POC CD4 testing using venous versus capillary blood in LMICs which
might otherwise influence clinical practice.
Keywords: CD4, Point of care testing, Diagnostic accuracy, Systematic review, Meta-analysis

Background
Increased testing of those at risk of HIV infection and
improving access to antiretroviral therapy (ART) particularly in the most HIV-affected regions is a recognized global strategy to end the AIDS epidemic.
However, only 15.0 million of an estimated of 36.9
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million (40.6 %) HIV-infected individuals have access to
ART [1]. Whilst new evidence endorses treatment of all
HIV-infected individuals [2, 3] and the World Health
Organization (WHO) guideline supports treatment of all
individuals regardless of CD4 count [4], the current
practical goal, one that is likely to apply in most resource limited countries into the foreseeable future, is to
achieve ART coverage of all HIV-infected adults with
low CD4 cell count (<350 cells/μL) before expanding
ART scale-up to people with higher CD4 cell counts.
Furthermore, for patients who are presenting late to

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Pham et al. BMC Infectious Diseases (2016) 16:592

care, a CD4 count is required as a baseline measurement
to identify the need for screening and prophylaxis for
major opportunistic infections which are often associated with low CD4 count and increased risk of mortality.
For treatment monitoring, CD4 count is important to
assess CD4-related risk of toxicity to Nevirapine and,
CD4 testing remains an important method to monitor
patients who are on treatment in settings where access
to viral load monitoring is still limited [5]. Thus, CD4
monitoring remains an essential and practical component of HIV care in the near future [6].
It has been known that barriers resulting in substantial
losses to the continuum of HIV care include poor access
to CD4 testing, particularly in disadvantaged and remote
areas where laboratory-based CD4 testing by flow cytometry is not available [7, 8]. Point-of-care (POC) testing is an effective strategy to overcome this challenge.
Findings from a number of field studies show that POC
CD4 testing can have a positive impact on the HIV continuum of care [9–15]. The use of POC CD4 in lower
and middle income countries (LMICs) where resources
for HIV care are most limited, is expected to produce
greatest clinical and economic impacts from both patient
and health system perspectives [16, 17]. With a number
of POC CD4 technologies available or in the pipe-line
[18], there is a need for consolidated evidence on the
performance of different POC CD4 tests, particularly in
LMICs, to inform decision-making related to selection
of an appropriate test in field settings. A systematic
review and a meta-analysis of test performance of
CD4 count technologies showed that POC CD4 test
is suitable for ART eligibility assessment at CD4
thresholds of 350 and 500 cells/μL [19, 20]. However,
these studies pooled data from both laboratory and
field evaluations in low and high income countries.
As there is evidence to suggest that performance of
the test varies significantly across evaluation settings
(laboratory vs clinic) in different countries [21, 22],
the question remains whether these study findings are
transferable, specifically to non-laboratory environments in LMICs. We, therefore, conducted a systematic review to assess the performance, acceptability
and feasibility in non-laboratory field settings of currently available or prototype commercial POC CD4
tests in LMICs. Here, we report on “field performance” of different POC CD4 tests; findings on “acceptability, feasibility” will be reported elsewhere.

Methods
This systematic review was conducted according to a
protocol developed using the preferred reporting items
for systematic reviews and meta-analyses (PRISMA)
statement [23].
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Literature search strategy

The search strategy was designed to identify any studies
describing POC CD4 tests. After an initial search for articles in Medline and Embase, an assessment of text
words within the title and abstract and of the index
terms used to describe these articles was conducted. A
subsequent full search using clearly established search
terms (see Additional file 1: Annex 1) was undertaken
across included databases, and adapted as appropriate to
the specifications for the respective databases: Medline,
Embase, CENTRAL, Cinahl, PsycINFO, Biological Abstracts, and Scopus. Web of Science and conference databases were also searched to identify relevant studies.
Reference lists of all identified reports and articles were
searched for additional studies. Moreover, searches were
conducted in grey literature resources such as conference websites (NLM Gateway, the British Library Conference and International AIDS Society and Conference
on Retroviruses and Opportunistic Infections) and clinical trials websites. Hand-searching and reference checking of citations and reference lists was undertaken.
Authors of relevant studies were contacted if insufficient
data were published. Government reports, letters to
editors, commentaries, editorials, non-peer reviewed articles and review articles were excluded. Studies conducted and funded by the manufacturer, if stated, were
also excluded.
Study selection

Inclusion criteria were that studies needed to be published between January 2005 and January 2015, written
in English language and conducted in LMICs (http://
data.worldbank.org/about/country-and-lending-groups).
Studies conducted in both LMICs and non-LMICs were
included if data from LMICs were presented separately.
Further eligibility criteria were defined using PICO (participants, interventions, comparisons, outcomes) format
[24]. Participants (P) included HIV positive, HIV negative and unknown HIV status persons aged ≥ 12 months.
For intervention (I), any of the following six commercially available POC CD4 testing platforms listed in the
UNITAID “2014 HIV/AIDS Diagnosis Technology Landscape” report [18] were included: (1) PointCare NOW™
(PointCare Technology Inc, Marlborough, MA, USA);
(2) Pima™ CD4 (Alere Inc, Waltham, MA, USA); (3)
Daktari™ CD4 Counter (Daktari Diagnostics Inc, Cambridge MA, USA); (4) CyFlow® CD4 miniPOC (Partec,
Munich, Germany); (5) BD FACSPresto™ (BD Biosciences, San Jose, CA, USA); and (6) MyT4™ CD4 Test
(Zyomyx Inc, Fremont, CA, USA). Results of POC CD4
test needed to be compared (C) to reference laboratorybased assays with outcomes (O) containing diagnostic
performance of POC CD4 test in field settings. All retrieved articles were checked for duplication; conference
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abstracts were excluded if duplicated with full-text articles.
Titles, abstracts and summaries of identified records were
screened for relevance. Retained records meeting the inclusion criteria were then examined in full text (Fig. 1).
Data extraction and data analysis

An electronic data extraction form was developed, pretested and finalized by consensus among authors. Data
extraction was conducted by one reviewer and verified
by the second using the data extraction form with 20 %
duplicate extraction. Quality of included studies was
assessed using EPHPP tool for quantitative studies [25]
and QUADAS tool for diagnostic accuracy studies [26].
Key measures used to evaluate performance of POC
CD4 tests were: (1) failure rates defined as the percentage of the total number of tests performed with an invalid result such that tests did not provide results and/or

Fig. 1 Selection process of included studies
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results could not be read. (2) Sensitivity and specificity
of index POC CD4 test at certain CD4 thresholds as
compared to the predicate method. (3) Misclassification
of index POC CD4 at certain CD4 thresholds. Misclassification is defined as the percentage of total HIVinfected individuals/blood samples tested with disagreement in results between POC CD4 and predicate
method for the purpose of identifying ART eligibility at
pre-specified CD4 threshold values of 200, 350 and 500
cells/μl; and (4) Difference in mean (bias) of CD4 counts
and limit of agreement between index POC CD4 and
predicate method. Bias included absolute and relative
bias defined as the mean absolute and/or relative
difference in CD4 count between the index POC CD4
and the predicate test. Limit of agreement was calculated
as the mean difference ± 1.96 standard deviation of the
difference.

Pham et al. BMC Infectious Diseases (2016) 16:592

A meta-analysis of diagnostic test accuracy (DTA) was
conducted of the Alere Pima™ CD4 (Pima) test through
application of a bivariate multi-level random effects
modeling approach [27], recommended for metaanalysis for Cochrane DTA reviews. The bivariate
random-effects model accounts for both the correlation
between study sensitivity and specificity estimates, and
also unobserved between-study heterogeneity in test performance through specification of a multi-level bivariate
normal regression approach. The bivariate model estimates sensitivity and specificity by modeling randomeffects across two levels; level 1 representing the withinstudy variability between sensitivity and specificity and
level 2 representing heterogeneity in diagnostic performance of the index test across studies. Using the multilevel bivariate model; sensitivity, specificity, positive and
negative likelihood ratios (±LR) of the Pima test were
estimated. In order to test for any difference in diagnostic performance across venous and capillary sample
methods, the multi-level bivariate random-effects model
was extended to include a covariate for blood sample
type. Post-estimation Wald tests were used to test the
joint (i.e. for sensitivity and specificity simultaneously)
effect of blood sample type on diagnostic accuracy. In all
multi-level analyses of pooled Pima test diagnostic performance, Huber/White variance estimation was used to
provide appropriate standard errors in instances where
multiple sets of diagnostic data were taken from a single
study [28]. Diagnostic statistics (Cook’s distance [using a
5 parameter model based cutoff >2] and standardized residual plots) from multi-level bivariate random-effect
models were examined to assess pooled sensitivity and
specificity estimates for outlier bias. Using Stata version
13.1 (Stata Corporation, TX, USA), both the user-written
Stata program Midas [29] and author-written code using
GLLAMM (Generalized Latent and Linear Mixed Modeling) [30] were used to provide key statistical output for
pooled multi-level bivariate random-effect model analyses of the diagnostic performance of the Pima test. The
user-written Stata program metandiplot [31] was used to
plot the hierarchical summary receiver operating characteristic (HSROC) curve [32] from observed study sensitivity and specificity estimates. Statistical significance
was assessed at 5 % in all analyses.

Results
Study characteristics

The initial search, after removing duplicates, yielded
2,919 records, among which 27 studies met all of the inclusion criteria and comprised 24 full-text articles and
three conference abstracts [33–35].
Twenty four studies (24) used Pima, two studies used
PointCare NOW, one used MyT4 as the index POC
CD4 test. Overall, the quality of included studies was
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considered between moderate and strong. The QUADAS
scores ranged from 7 to 12 (of a maximum score of 14)
with 63 % (12/19) of studies scoring between 10 and 12.
Among 22 studies reporting performance of POC CD4
test (Table 1), 19 (86 %) were conducted in sub-Saharan
countries and three others were in India [36], Brazil [37]
and PNG [38]. CD4 predicate testing technologies used
as reference include FACSCalibur, FACSCount, Panleucogating (PLG) flow cytometry, Partec CyFlow and
GUAVA. Only one study performed duplicate testing
[39], and three studies performed precision testing of
the reference method on a subset of whole blood samples (3 – 15 blood specimens) [40–42]. Among 19 studies reporting diagnostic performance of Pima, only 11
studies provided data required for and then subsequently
included in the meta-analyses.
Performance of POC CD4 tests in field settings
Failure rates

For Pima, studies with capillary blood reported a wide
range of failure rates from 2 % [43] to 23.3 % [44]. Studies
using venous blood in various clinical settings reported
failure rates ranging from 4.8 to 15.2 % [40, 44–46]. One
study reported a zero “no read” error in laboratory evaluation of Pima with venous blood, however, in field evaluations in different clinical settings failure rate was recorded
at a wide range from 6.8 to 20.9 % [22]. For PointCare
Now the failure rate varied from 2.9 % in one study [41]
to 9.2 % in another [47]. With MyT4 CD4 test a studywide error rate of 9.6 % was recorded [48].
Detailed performance data of Pima is presented in
Table 2.
Misclassification, sensitivity and specificity

When CD4 count testing was conducted using a venous
blood specimen Pima showed lower misclassification
and higher probabilities of correctly identifying patients
eligible for ART across studies and different reference
methods. At a CD4 threshold of 350 cells/μl, the total
misclassification probability of Pima test using venous
blood was 4.0–12.2 % [44, 49] versus 6.7–17 % for capillary blood [39, 50]. Pima point estimates for sensitivity
and specificity ranged from 89–99 % and 77–93 % for
venous blood; and 79–98 % and 80–99 % for capillary, respectively. For PointCare Now, one study [47]
reported site-specific sensitivity ranging from 38 to
63 %, resulting in misclassification of 50 % of patients
tested as ineligible for ART; another study [41] reported a lower misclassification of 6 % of patients as
ineligible for treatment. For MyT4 CD4, the sensitivity and specificity of the test were 88 and 84 % when
compared to FACSCalibur and 95 and 88 % as compared to FACSCount [48].

Pham et al. BMC Infectious Diseases (2016) 16:592

Page 5 of 17

Table 1 Characteristics and Quality assessment of studies included in the review
First author,
year

Study population/Study setting

Study design/
Sample size

Sample

Intervention Comparison

Study
qualitya

Rathunde,
2014 [37]

Adult HIV patients at specialized
ambulatory facilities in academic
tertiary care hospital in Curitiba,
Brazil

Cross-sectional
(N = 107)

Venous

Alere Pima™ FACSCalibur
CD4 (Pima)

9

Galiwango,
2014 [49]

HIV infected patients (pre and
experienced ART persons) at
field clinics in Rakai, Uganda

Cross-sectional
(N = 903)

Venous

Pima

FACSCalibur

10

van Rooyen,
2013 [15]

Known HIV-positive individuals
older than 18 years in
KwaZulu-Natal, South Africa (SA)

Prospective
Capillary (Pima);
cohort (N = 671) venous (FACSCalibur)

Pima

FACSCalibur

Moderate

Myer,
2013 [45]

HIV infected pregnant women
at a single large antenatal clinic
in Cape Town, SA

Cross-sectional
(N = 546)

Venous

Pima

Beckman-Coulter 8
PLG technology

Mnyani,
2012 [51]

HIV infected pregnant women
at first ANC visit to Chiawelo
clinic in Johannesburg, SA

Cross-sectional
(N = 305)

Capillary (Pima);
venous (Ref. tests)

Pima

Beckman Coulter 10
Flow Cytometer

Mwau,
2013 [53]

Patients attending 9 health
facilities (for HIV treatment
and care) offering CD4 count
in Kenya

Cross-sectional
(N = 1539)

Venous (Pima & reference Pima
methods); capillary (Pima)

FACSCount,
Partec Cy-flow,
GUAVA and
FACSCalibur

Glencross,
2012 [22]

Adult HIV patients attending
(1) Hospital based antenatal
HCT clinic in Johannesburg-phase
II (2) Two Primary health care HCT
clinic in Limpopo province-phase IIIA;
and (3) Inner-city primary health care
clinic in Johannesburg, South
Africa-phase IIIB

Cross-sectional
(N = 91; N = 96;
N = 139)

Venous and capillary

Pima

Simplified single 12
platform (SP)
PLG CD4

Thakar,
2012 [36]

HIV positive patients aged 18–60
attending 21 ART centers in different
parts of India

Cross-sectional
(N = 1790)

Venous and capillary

Pima

FACSCalibur;
FACSCount;
Partec CyFlow

12

Manabe,
2012 [46]

HIV infected patients at Adult
Infectious Diseases Institute Clinic
in Mulago Hospital, Kampala, Uganda

Cross-sectional
(N = 206)

Venous and capillary

Pima

FACSCalibur

11

Jani,
2011 [39]

HIV infected individuals attending 2
primary health care ART clinics in
Maputo, Mozambique

Cross-sectional
(N = 697)

Capillary (Pima);
venous (Ref. tests)

Pima

FACSCalibur

7

Diaw,
2011 [44]

Patients (adults & children; HIV +/−)
presenting for HIV follow-up at three
out-patient clinic & one lab in Dakar,
Senegal

Cross-sectional
(N = 300)

Venous (200 patients);
Pima
capillary (finger/heel-prick)
100 patients

FACSCount

11

MtapuriZinyowera,
2010 [50]

Newly diagnosed HIV positive patients
at a VCT center in Harare, Zimbabwe

Cross-sectional
(N = 165)

Capillary (Pima);
venous (Ref. tests)

Pima

FACSCalibur

11

Wade, 2014
[40]

HIV infected patients presenting for
routine CD4 testing at infectious
disease clinic in Dar es Salam, Tanzania

Cross-sectional
(N = 200)

Capillary (Pima);
venous (Ref. tests)

Pima

FACSCalibur

11

Wade,
2013 [42]

(Anonymous) HIV infected patients
attending normal CD4 test monitoring
and HIV-negative donors from blood
bank of Regional Hospital and two
Healthcare Centers in Ziguinchor,
Senegal

Cross-sectional
(N = 128)

Venous

Pima

FACSCount

11

Gous,
2013 [52]

HIV infected patients > 18 years old
Cross-sectional
visiting comprehensive care management (N = 300)
and treatment clinic for ART initiation
or monitoring at Tshwane District Hospital
in Pretoria, SA

Capillary (Pima);
venous (Ref. tests)

Pima

PLG CD4 FC 500 10

8
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Table 1 Characteristics and Quality assessment of studies included in the review (Continued)
Malagun,
2014 [38]

HIV infected adults >18 year old
attending one urban (Heduru HIV
clinic at Port Moresby General Hospital,
Port Moresby) and 2 rural
(Asaro District Health Centre and
Kainantu Rural Hospital) clinics in
Papua New Guinea

Cross-sectional
(N = 237)

Venous

Pima

FACSCount

Picken,
2014 [43]

HIV positive mother of children
with CD4 count < 500 cells/μl and
not on ART at Tygerberg hospital,
Cape Town, SA

Cross-sectional
(N = 52)

Capillary (Pima);
venous (Ref. tests)

Pima

Beckman Coulter 11
FC 500 MPL®

Mwau,
2014 [48]

HIV infected patients ≥ 18 years old
at Comprehensive clinics of 2 health
care facilities in Busia county of
Western province, Kenya

Cross-sectional
(N = 276)

Capillary (Pima);
venous (Ref. tests)

MyT4 POC
CD4

FACSCalibur and 11
FACSCount

Gumbo,
2013 [41]

HIV infected adult patients attending
Harare Central hospital opportunistic
infection clinic, Zimbabwe

Cross-sectional
(N = 104)

Venous

PointCare
NOW

BD FACSCalibur

Bergeron,
2012 [47]

HIV infected adult patients; unknown
HIV status; and HIV infected children
aged 12–59 months attending:
(1) the Instituto Nacional de Saude
(INS) Maputo, Mozambique; (2) the
Institute of Tropical Medicine of
Antwerp (Belgium) in Tete,
Mozambique; (3) Wits University,
Johannesburg, SA

Cross-sectional
(N = 472)

Venous

PointCare
NOW

FACSCalibur and 8
the EPICS- XL

Zeh,
2014 [35]

HIV infected patients in Western Kenya

Cross-sectional
(N = 147)

Venous and capillary

Pima

FACSCalibur

-

Arnet N,
2013 [33]

HIV infected patients from 5 PMTCT
and HIV treatment sites in
Dar-es-Salaam, Tanzania

Cross-sectional
(N = 1060)

Venous and capillary

Pima

FACSCalibur

-

11

9

HCT HIV counseling and testing, ART Antiretroviral therapy, VCT Voluntary counseling and testing; PMTCT Prevention of mother to child transmission
a
Study quality assessment using EPHPP tool (strong/moderate/weak), or QUADAS score (out of 14)

Meta-analysis of diagnostic accuracy of the Alere
Pima™ CD4 in field testing We aimed to conduct categorical data analysis of diagnostic accuracy of Pima at
CD4 350 and 500 cells/μl cut-offs. However, only three
included studies [40, 42, 49] reported data required for
meta-analysis at the 500 cut-off. Thus only analysis at a
CD4 threshold of 350 cells/μl was performed. Required
data including number of true positive, false positive,
false negative and true negative cases were reported in
the literature from 9 studies [38, 40, 42, 43, 45, 49–52].
Data from two studies [37, 53] were received from the
authors following email contact, yielding a final dataset
comprising 11 studies for the meta-analysis. Among
these, two studies [40, 53] reported Pima test results for
both venous and capillary blood, and these data were
treated in meta-analyses as independent study results
but with model standard errors corrected for the lack of
independence in observations. Five studies [37, 38, 42,
45, 49] reported the results with venous and four studies
[43, 50–52] with capillary blood only.
Examination of post-estimation of diagnostic statistics
after preliminary meta-analyses provided some evidence
of model outlier bias, with two studies [53] (capillary)

and [38] (venous) showing model discrepant test sensitivity and specificity (Cook’s distances: 2.12 and 3.65 respectively). However, diagnostic test data from these
studies were included in the pooled meta-analysis after
sensitivity analysis, with outlying cases excluded, indicated no marked difference in pooled estimates (included versus excluded sensitivity and specificity: 92 vs.
92 % and 87 vs. 88 %, respectively).
Diagnostic accuracy of the test in field settings was
relatively high, with pooled sensitivity and specificity
estimated at 92 % (95 % CI = 88–95 %) and 87 % (95 %
CI = 85–88 %) respectively (Fig. 2). Further, pooled
positive and negative likelihood ratios were also at
levels indicating relatively strong diagnostic performance of Pima (+LR = 7.0, 95 % CI = 6.1–7.9; −LR =
0.09, 95 % CI = 0.06–0.13). Figure 3 shows observed
sensitivity and specificity plotted for each included
study with the HSROC curve, the pooled estimate
and 95 % confidence and prediction contours.
Bivariate random-effect hierarchical models estimating
pooled diagnostic performance with a covariate for
blood sample type showed some potential difference in
summary sensitivity and specificity by blood sample

Author,
year

Performance of Pima on capillary blood
Bias/LoA; Sample size (N)

Author, year Performance of Pima on venous blood

Sensitivity
Specificity

Total
Failure
Misclassification rate

Bias/LoA Sample size (N)

Sensitivity
Specificity

Total
Misclassification

Failure rate

Reference test = FACSCalibur
(van
Rooyen,
Barnabas
et al. 2013)
[14]

Mean bias: 16
cells/μl (LoA: −1
to 32; N = 193)

Not reported
(NR)

NR

NR

(Rathunde, Bias/LoA NR; N = 107
Kussen et al.
2014) [32]

At CD4 threshold
of 350 cells/μl:
Sensitivity 94 %
Specificity 93 %

NR

NR

(Jani, Sitoe
et al. 2011)
[34]

Accurate absolute
counts

NR

At CD4
thresholds of
200 cells/μl:
5.2 %

NR

(Galiwango,
Lubyayi et
al. 2014)
[45]

Pima significantly
underestimate CD4
count particularly
at higher CD4 count.

At CD4 threshold
of 350 cells/μl:
Sensitivity 88.6 %
specificity 87.5 %

12.2 %

NR

Bias: −34.6 cells/μl
(LoA: −219.8 to +150.6;
N = 903)

At CD4 threshold
of 500 cells/μl:
Sensitivity 96.1 %
specificity 83.0 %

9.5 %

At CD4 threshold
of 350 cells/μl (in
those ≥ 5 years
old N = 389):
Sensitivity: 89.7 %
Specificity: 87 %

11.9 % (47/396)

At CD4 threshold
of 200 cells/μl
(in those ≥ 5 years
old N = 389):
Sensitivity: 86.7 %
Specificity: 94.1 %

NR

Bias: −52.8 cell/μl
(LoA: −250.9
to 145.2; N = 135).
Bias was smaller
at lower CD4
count (<500: −24.4)
than at higher CD4
count (>500: −107.9).

At CD4
thresholds of
350 cells/μl:
17 %

At 350 cut-off: +5.1
cells/μl (LoA: −126.6
to +136.8) vs −51.0
cells/μl (LoA: −245.4
to +143.4)

Pham et al. BMC Infectious Diseases (2016) 16:592

Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used

At 500 cut-off:-10.9
cells/μl (LoA: −147.3
to +125.5) vs −66.3
cells/μl (LoA: −286.6
to +154.0)
(MtapuriZinyowera,
Chideme
et al. 2010)
[46]

Mean bias: 7.6
cells/μl
(LoA: −173.8
to +189.0).

At CD4 threshold 6.7 %
of 200 cells/μl:
Sensitivity: 95.1 %
Specificity: 91.6 %

Bias was small
at both low
(<400 cells/μl)
and high
(>400 cells/μl)

With sub12.8 %
samples of FACSCalibur results of
(100 to 300 cells/
μl)

(Mwau,
Adungo et
al. 2013)
[49]

Bias: −64.8 cells/μl
(LoA: −332.5 to +203.0;
N = 396)

NR
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At CD4 threshold 6.7 %
of 350 cells/μl:
Sensitivity: 94.7 %
Specificity: 87.5 %

NR

With sub14.1 %
samples of FACSCalibur results of
(200 to 500 cells/
μl)
(Thakar,
Relative bias: −9.1 %;
Mahajan et LoA: −46 % to 27 %;
al. 2012)
N = 175
[31]

NR

NR

NR

(Thakar,
Mahajan et
al. 2012)
[31]

Among patients with
CD4 < 350 cells/μl:
relative bias: +4 %
(N = 121)

At CD4 threshold
of 350 cells/μl:
Sensitivity: 96 %;
Specificity: 91 %

NR

NR

(Manabe,
Bias: −66.3 cells/μl
Wang et al. (LoA: −83.4 to +49.2;
2012) [41] p < 0.001; N = 176)

NR

NR

17.7 %

(Manabe,
Wang et al.
2012) [41]

Bias: −68.5 cells/μl
(LoA: −79.6 to −57.4;
p < 0.001; N = 206)

NR

NR

8.1 %

Relative mean bias: −9.4
% (LoA: −54.4 to +35.6)

At CD4 threshold
of 200 cells/μl:
Sensitivity: 98 %
Specificity: 95 %

3 % (14/440)

6.5 % (13/200)

Sub-samples of CD4 ≤ 200:
1 % (LoA: −75 to 77);
CD4 200–500: −11 %
(LoA: −46 to +25);
CD4 ≥ 500: −15 %
(LoA: −34 to +4)

At CD4 threshold
of 350 cells/μl:
Sensitivity: 97 %
Specificity: 80 %

9 % (40/440)

At CD4 threshold
of 500 cells/μl:
Sensitivity: 99 %
Specificity: 78 %

NR

At CD4 threshold
of 350 cells/μl:
Sensitivity: 94 %
Specificity: 95 %

NR

Bias was smaller
at lower CD4
counts (−10.8 cells/μl;
LoA: −27.3 to +5.6;
p = 0.19 for CD4
range 0–250 cells/μl)
and much greater
at higher CD4 count
(−120.6 cells/μl;
LoA: −162.8 to −78.4;
p < 0.001 for
CD4 > 500 cells/μl)
(Wade,
Daneau et
al. 2014)
[35]

Relative bias: −0.9 %;
(LoA: −57.3 to +55.6);
N = 200

At CD4
4 % (16/410)
threshold of 200
cells/μl:
Sensitivity:
100 %
Specificity: 94 %

Sub-samples of
CD4 ≤ 200: 5 %
(−78 to +89);
CD4 200–500: 0 %
(−49 to +49);
CD4 ≥ 500: −8 %
(−49 to +34)

13.4 % (55/410)
At CD4
threshold of 350
cells/μl:
Sensitivity: 87 %
Specificity: 90 %

Bias: −44 cells/μl;
N = 147

4.5 % (9/ (Wade,
200)
Daneau et
al. 2014)
[35]

At CD4
NR
threshold of 500
cells/μl:
Sensitivity: 97 %
Specificity: 82 %
At CD4
NR
threshold of 350
cells/μl:
Sensitivity: 86 %
Specificity: 99 %

NR

(Zeh,
Inzaule et
al. 2014)
[30]

Bias: −86 cells/μl; N = 147

NR
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(Zeh,
Inzaule et
al. 2014)
[30]

Bias was smaller at
lower CD4 counts: +13.6
cells/μl (LoA: 2.52 to 24.7;
p = 0.02 for CD4 range
0–250 cells/μl) and
much greater at higher
CD4 counts: −121.7
cells/μl (LoA: −147.9
to −95.4; p < 0.001
for CD4 > 500 cells/μl)
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Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used (Continued)

(Arnett N
2013) [28]

Bias: 0 (PIMA –Microtube) NR
and −20 cell/μl
(PIMA –direct);
N = 1060

NR

8.6 %
(Microtube)
and
10.1 %
(direct)

(Arnett N
2013) [28]

Bias: −10 cells/μl

NR

NR

7.7 %

(Mwau,
Adungo et
al. 2013)
[49]

Mean bias: +7.8
cells/μl (LoA: −168.9
to 184.4; N = 822)

At CD4 threshold
of 350 cells/μl
(in those ≥ 5 years
old N = 813):
Sensitivity: 79.4 %
Specificity: 83.4 %

NR

NR

At CD4 of 200
cells/μl (in those ≥
5 years old N = 813):
Sensitivity: 83 %
Specificity: 98.2 %

NR

Reference test = FACSCount
(Mwau,
Adungo et
al. 2013)
[49]

(Diaw,
Daneau et
al. 2011)
[39]

Mean bias: +8.6
cells/μl (LoA: −235.4
to 252.7; N = 521)

Of 95 HIV (+) patients,
Absolute bias: −39
cells/μl (LoA: −258
to +179)

At CD4
16.5 % (86/521) NR
threshold of 350
cells/μl:
Sensitivity:
79.4 %
Specificity:
86.9 %

At CD4
5.3 % (5/95); of
threshold of 200 finger-prick
cells/μl:
samples
Sensitivity: 91 %
Specificity: 97 %

Sub-samples of CD4 <
200: bias: +15 cells/μl
(LoA: −89 to 118);
Sub-samples of
CD4 > 500: bias: −112
cells/μl (LoA: −429
to 204)

14 %
total;
23 % in
one
study
site

(Thakar,
Mahajan et
al. 2012)
[31]

Among patients with
CD4 < 350 cells/μl:
Mean relative bias: −5 %
(N = 206)

At CD4 threshold
of 350 cells/μl:
Sensitivity: 92 %;
Specificity: 91 %

NR

(Diaw,
Daneau et
al. 2011)
[39]

For 100 HIV(+) patients,
Absolute bias: −32
cells/μl (LoA: −146
to +84)

At CD4 threshold
of 200 cells/μl:
Sensitivity: 90 %

4%
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Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used (Continued)

4.8 %

Specificity: 98 %

At CD4
NR
threshold of 350
cells/μl:
Sensitivity: 91 %;
Specificity: 80 %

Sub-samples of
CD4 < 200:
bias: +9.4 cells/μl
(LoA: −76 to 94);
Sub-samples of CD4 > 500:
bias: −77 cells/μl
(LoA: −217 to 63)

At CD4 threshold
of 350 cells/μl:

NR

Sensitivity: 98 %
Specificity: 79 %

For 99 HIV(−) controls
Absolute bias: −125
cells/μl (LoA: −434
to +184 cells/μl for
all ranges of CD4
(Wade,
Diaw et al.
2013) [37]

At CD4 threshold
of 200 cells/μl:
Sensitivity 95 %
Specificity 96 %

NR

NR
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Bias: −30 cells/μl
(LoA: −160 to 101;
N = 128: 111 HIV+ &
17 HIV-)

Sub-samples of CD4 < 200: At CD4 threshold
Bias: +6.0 cells/μl
of 350 cells/μl:
(LoA: −39 to +51)
Sensitivity 97 %
Specificity 90 %

(Malagun,
Nano et al.
2014) [33]

Sub-samples of
CD4 > 500: Bias: −65
cells/μl (LoA: −224
to +93)

At CD4 threshold
of 500 cells/μl::
Sensitivity 99 %
Specificity 72 %

Urban clinic: Bias: −46.4
cells/μl (LoA:-199.8
to 107.0); N = 139

At CD4 threshold
of 350 cells/μl:
Sensitivity: 99.2 %;
specificity: 77.1 %

10.7 %

Error rate:
5.1 %

Bias: −22.7 cells/μl
(LoA: −174.6 to 129.2);
N = 546.

At CD4 threshold
of 350 cells/μl:

10 %

Bias increased with
increasing gestational
age

Sensitivity: 92 %

61/546 samples
required 83
additional test;
4 returned no
result due to
repeated
machine errors

NR

10.4 % (5/48) &
20.9 % (9/43)
for 2 devices

Among 32 patients with
CD4 < 350: 10 patients
(31.2 %) would have
missed ART (upward
misclassification)

6.8 % (7/103)

Rural clinic: Bias: −55.8
cells/μl (LoA: −182.9
to 71.2); N = 98
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Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used (Continued)

Reference test = Beckman-Coulter flow cytometry using Pan-leucogating (PLG) method
(Mnyani,
Bias: −20.5 cells/μl
McIntyre et (LoA: −175.0
al. 2012)
to +133.9;
[47]
p < 0.001;
N = 296)

(Glencross,
Coetzee et
al. 2012)
[42]

At CD4
10.8 %; mostly
threshold of 350 in favor of
cells/μl:
patient
treatment.

NR

No significant
variability in the
level of agreement
related to age and
gestational age

Sensitivity: 93 %
(95 % CI 87–96),
Specificity: 86 %
(95 % CI 80–91)

Phase II (Hospital
ANC clinic: Bias: −37.9
cells/μl (LoA: −389.1
to 309.8; N = 77

NR

NR

NR

Phase IIIA Rural/poor
resourced clinic:
Not applicable (NA)

NA

NA

NA

(Myer,
Daskilewicz
et al. 2013)
[40]

Specificity: 89 %;
Sensitivity & specificity
did not vary significantly
across gestational age

(Glencross,
Coetzee et
al. 2012)
[42]

Phase II (Hospital ANC
clinic: Bias: −19.6 cells/μl
(LoA: −149.1 to 110.0;
N = 91)
Substantial, clinically
significant difference
to predicate: Bias +105.7
cells/μl (LoA −336.1
to 547.5; N = 96)
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Larger bias and wider
LoA for samples with
CD4 < 350: +131.4
cells/μl (LoA: −275.8
to +538.6; N = 32) as
compared to samples
with CD4 < 500: +102.3
cells/μl (LoA: −289 to
493.6; N = 52) = > increasing

NR

error at CD4 range of
less than 350 cells/μl

(Gous,
Scott et al.
2013) [48]

(Picken,
Williams et
al. 2014)
[38]

Phase IIIB well resourced
clinic: NA

NA

NA

Results showed considerably
less bias and tighter
LoA variance, as
compared to phase IIIA,
irrespective of lancet
used: lancet 1 (Sarstedt)
bias: +8.9 cells/μl
(LoA: −211.1
to 229; N = 87);
lancet 2 (Caralet Blue)
bias: −11.2 cells/μl
(LoA: −147 to 124;
N = 52)

Phase I: Multiple
POC testing from
multiple finger-sticks:
mean bias was −32
cells/μl (N = 98)
PIMA overestimate
at low CD4 count
(<350) and underestimate
at high CD4 count
(>500 cells/μl)

At CD4
12.4 %
threshold of 350
cells/μl:
Sensitivity
86.4 %,
Specificity
88.5 %

16.3 %

NA

NA

NA

NA

Phase II: Multiple
POC testing from
single finger-stick:
Mean bias - 30
cells/μl (N = 73)

At CD4
4.1 %;
threshold of 350
cells/μl:
Sensitivity
97.5 %,
Specificity 95 %

19.2 %

NA

NA

NA

NA

Bias: 23.8 cells/μl
(LoA: −166.1 to
213.8; N = 50

10 %
At CD4
threshold of 350
cells/μl:
Sensitivity:
88.9 %,
specificity:
90.6 %

1.9 %

NR

NR

Mean bias: −24.2 cells/μl
(LoA: −277.6 to +229.3; N
= 407)

NR

NR

NR

NA

9 % (14/153)
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Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used (Continued)

Reference test = Partec Cyflow
(Mwau,
Adungo et
al. 2013)
[49]

Mean bias: −10.0
cells/μl (LoA: −261.4
to 241.4; N = 162)

NR

(Mwau,
Adungo et
al. 2013)
[49]
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(Thakar,
Mahajan et
al. 2012)
[31]

Among patients with CD4
< 350 cells/μl: mean
relative bias +8 % (N =
550)

At CD4 350
threshold:
Sensitivity: 91 %;
Specificity: 96 %

NR

NR

(Mwau,
Adungo et
al. 2013)
[49]

Mean bias: −0.3 cells/μl
(LoA: −315.0 to 315.6; N =
191)

NR

NR

NR

Reference test = GUAVA
(Mwau,
Adungo et
al. 2013)
[49]

Mean bias: +23.9
cells/μl (LoA −329.6
to 281.9; N = 176)

NR

LoA limit of agreement, POC point-of-care, ANC antenatal care

NR

NR
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Table 2 Performance of Pima stratified by venous and capillary blood collection and presented by reference test used (Continued)
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Fig. 2 Point estimates‡ of diagnostics performance of Pima in field settings at CD4 350 cells/μl cut-off

type. Using venous samples, pooled sensitivity was 94 %
(95 % CI = 89–97 %) and pooled specificity 86 % (95 %
CI = 82–89 %), while using capillary blood pooled sensitivity was 89 % (95 % CI = 83–93 %) and specificity 87 %
(95 % CI = 86–89 %). However, a post-estimation test of
the joint effect of blood sample type on the sensitivity
and specificity of Pima showed that these differences in
diagnostic accuracy did not reach statistical significance
(Wald χ2(2) = 4.77, p = 0.09).
Bias and limit of agreement (LoA)

Overall, Pima showed a better performance with venous
compared to capillary blood samples with a smaller
range of bias and tighter LoA across studies with different predicate technologies. Studies reported absolute
bias of Pima at CD4 > 500 cells/μl ranging from −66.3
cells/μl (LoA: −286.6, +154.0) for venous [49] to −120.6
cells/μl (LoA: −162.8, −78.4) for capillary blood [46]. At
lower CD4 ranges, bias were reported at +15 cells/μl
(LoA: −89 to +118) for CD4 < 200 cell/μl using capillary
blood [44]; and +5.1 cells/μl (LoA: −126.6, +136.8) for
CD4 < 350 cell/μl using venous sample [49]. These data
suggest that Pima overestimates the CD4 count at lower

CD4 ranges and underestimates the CD4 count at higher
ranges; the bias was also increased at higher CD4
counts.

Discussion
Findings of this review suggest that POC CD4 testing
can provide reliable results for making treatment decisions among HIV patients in LMICs. This review highlights the need for published data regarding the field
evaluation of available POC CD4 tests, particularly in
low-resource settings where these novel technologies are
already demonstrating significant impact on the continuum of care for HIV-positive persons. Among six
current or prospective commercially available POC CD4
technologies, only three have published studies that
meet inclusion criteria and most of these used Pima as
the index test. Among 19 studies reporting Pima performance data, 11 studies provided data required for
meta-analysis of diagnostic test accuracy.
Findings on Pima performance from two studies using
both venous and capillary blood showed that CD4
counts on venous blood samples produced more accurate results than capillary blood, with lower failure/error
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Fig. 3 HSROC curve from multi-level bivariate random effects model estimation of diagnostic performance of Pima at CD4 350 cells/μ cut-off¥:
plots observed sensitivity and specificity, diagnostic summary point, 95 % confidence and prediction contours.

reading rate, the authors suggest that variation in test results was likely due to quality of capillary sampling [22,
44]. However, other evidence supports the use of either
venous or capillary specimens [35, 40]. Though not statistically significant, our meta-analysis shows that there
is a trend towards a better performance of the test with
venous blood, with a sensitivity of 0.94 for venous and
0.89 for capillary blood (p = 0.09) in identifying HIVpositive person eligible for ART at a cut-off of 350 cells/
μL. If this is a true difference in performance of the test,
the use of venous blood when using Pima for ART eligibility assessment would be preferable as it could reduce
false negative test results which represent patient’s
missed opportunities for timely treatment initiation.
An observed wide range of failure rate of the Pima
technology across studies is another attribute that needs

further attention. Apart from technical and operational
characteristics of the test, evidence from field studies
suggests that performance of the test operator influences
the accuracy of diagnostic test in the field [11, 22].
Therefore, the quality of training on POC testing for test
operators and their supervisors becomes critically important to ensure effectiveness and efficiency of the
technology in field settings. Of note, few of the included
studies mentioned the effect of staff training on performance of POC CD4 test and none described details
of the training program.
Bias in assessing the diagnostic accuracy of any new
test could arise from faulty results of the reference test
itself as there is no gold standard for CD4 testing although single platform flow cytometry has assumed that
position. Thus evidence of participation and successful
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performance in external quality assurance (EQA) programs and performing duplicate tests on a sample using
the predicate test are worthy recommendations in order
to ensure the highest accuracy of predicate results. In
this review only half of the included studies described
EQA participation for the reference test and only one
study conducted duplicate testing.
In order to better inform the decision making process
on selection and adoption of POC CD4 testing in
LMICs, further studies on currently and newly available
POC CD4 technologies in various level settings and different geographic regions are needed. It is recommended
that the quality of studies as well as quality of study
reporting should be improved by following established
standards [26, 54] and the focus of these future studies
should not only be on test diagnostic accuracy but also
on implementation aspects of the test, aiming at providing practical evidence to inform effective implementation strategies of POC CD4 testing.
There are two published systematic reviews and metaanalyses of the performance of POC CD4 tests, one by
Scott et al. [19] and one by Peeling et al. [20]. In comparison, our review included 22 peer reviewed publications, providing a large increase in analysis of published
work on POC CD4 technologies compared to the other
reviews. Importantly, our study differed from the previously published reviews in that only studies conducted
in field settings were included and thereby specially
assessed field performance of the Pima. We demonstrated that misclassification by Pima, particularly with
the use of capillary blood samples under field conditions,
can be higher than that under a laboratory environment;
thus our data vary with the earlier study where the reported probability of Pima misclassification was less than
10 % [20]. A significant methodological strength of our
meta-analysis is the direct estimation of the joint effect
of blood sample type on Pima sensitivity and specificity
simultaneously, using a bivariate multi-level random effect model with pooled study data. This is a significant
improvement in statistical robustness compared to the
simple comparison of 95 % CI estimates for sensitivity
and specificity applied in the other meta-analysis [19].
Encouragingly, our results, in line with findings from
other reviews, confirm that POC CD4 tests also perform
well if assessed specifically in field settings. Pima therefore has the potential for further deployment for ART
eligibility assessment and treatment monitoring, especially in areas where laboratory-based CD4 testing is not
available or difficult to access.
This review has some limitations which may affect the
generalization of the findings. First, we included only published, peer-reviewed journal articles in English and this
inclusion may overlook data from studies published in
other languages or unpublished data from evaluations/
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studies conducted by government agencies, reference facilities or similar institutions. The inclusion of conference
abstracts has it strengths in limiting publication bias; however, confidence in these findings is limited as the quality
of these studies has not been assessed via formal peer review. Second, only three of the six POC CD4 technologies
found in this review were published with field study data
and one technology (Pima) featured most prominently in
the included studies. This presents challenges in terms of
generalizing many of the findings of the review to “all”
POC CD4 tests as it may be subjected to reporting bias.
Third, interpretation of findings from meta-analyses of
this review should be contextualized in terms of the limited diagnostic test data available from published studies.
This limitation cannot be overcome until more data from
field studies of different POC CD4 technologies, including
the Pima, are available.

Conclusions
Findings of this review suggest that field studies of POC
CD4 tests currently available on the market and those
eagerly anticipated, conducted in LMICs where they are
needed the most, remain much in need. The Pima™ CD4
showed acceptable diagnostic test accuracy using either
venous or capillary blood. Existing evidence indicates
that POC CD4 testing, can provide reliable results under
field conditions and could play an important role in HIV
continuum of care. This remains true, despite the changing landscape with respect to guidelines for ART initiation. Whilst evidence supports increasingly earlier
commencement of treatment at an individual and community level, the financial reality is that in many parts of
the world priority for ART initiation must still continue
to be given to those with evidence of declining immune
function. Further evidence is needed to ensure that efficacy is acceptable with both venous and capillary blood
samples in field settings.
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